EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics, safety and preliminary efficacy of conbercept eye drops for corneal neovascularization: Results from phase I/IIa studies

Qi Shen, Pei Shu, Zhenlei Wang, Jin Yuan, Zhiqiang Pan, Cheng Pei, Jing Hong, Yanning Yang, Mingchang Zhang, Xiao Ke, Xinguo Wang, Zhu Luo iD und 2 weitere

British Journal of Clinical Pharmacology · 17.08.2026

DOI: 10.1002/bcp.70707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 17.08.2026. Verfasst von Qi Shen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Chengdu Kanghong Biotechnology Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Vascular endothelial growth factor (VEGF) drives corneal neovascularization (CorNV), yet no anti‐VEGF eye drops are clinically available. We report phase I/IIa trials of KH906, a novel topical anti‐VEGF agent.

Methods

Trial 1 was a phase I, open‐label, dose‐escalation study in healthy adults receiving KH906 at 0.1, 0.5, or 1.0 mg/mL. Trial 2 was a phase I, multicentre, open‐label, dose‐escalation study in patients with CorNV at the same doses. Trial 3 was a phase IIa, randomized, double‐masked, placebo‐controlled study assigning patients 1:1:1 to 0.5 mg/mL KH906, 1.0 mg/mL KH906, or placebo. Primary endpoints were safety, tolerability and pharmacokinetics (Trials 1 and 2) and safety, tolerability and efficacy (Trial 3).

Results

From 10 December 2018 to 16 June 2021, 18 healthy participants and 39 patients with CorNV were enrolled. One treatment‐related adverse event occurred: a mild corneal epithelial defect in the 1.0‐mg/mL group in Trial 3. No serious or other drug‐related adverse events were observed. In Trial 2, KH906 reduced the CorNV area and vessel length. In Trial 3, at Day 28, mean changes in CorNV area were −1.2 (0.8), −1.6 (1.1) and −0.7 (1.1), and mean changes in CorNV length were −8.0 (7.3), −6.6 (5.9) and −1.7 (7.9), in the 0.5‐mg/mL KH906, 1.0‐mg/mL KH906 and placebo groups, respectively. The 1.0‐mg/mL dose produced greater reduction of the CorNV area than lower doses, indicating a dose–response effect.

Conclusions

KH906 appears safe and well tolerated and demonstrates preliminary efficacy in reducing CorNV, with higher doses showing greater effect, supporting further clinical development.

Schlagwörter

Stichwörter der Autor:innen

anti‐VEGF eye dropscorneal neovascularizationphase I studyphase IIa study

Autor:innen und Institutionen

  • Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China.
  • Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, China.
  • Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Pharmacy, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital, Sichuan University, Sichuan University, Chengdu, China.
  • Corneal & External Diseases, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
  • Ophthalmology and Corneology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Zhu Luo

Förderung

  • Chengdu Kanghong Biotechnology Co. Ltd

Zitieren

APA

Shen, Q., Shu, P., Wang, Z., Yuan, J., Pan, Z., Pei, C., Hong, J., Yang, Y., Zhang, M., Ke, X., Wang, X., Luo, Z., Ma, K., & Deng, Y. (2026). Pharmacokinetics, safety and preliminary efficacy of conbercept eye drops for corneal neovascularization: Results from phase I/IIa studies. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70707

Vancouver

Shen Q, Shu P, Wang Z, Yuan J, Pan Z, Pei C, et al. Pharmacokinetics, safety and preliminary efficacy of conbercept eye drops for corneal neovascularization: Results from phase I/IIa studies. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70707

BibTeX
@article{Shen2026,
  author = {Shen, Qi and Shu, Pei and Wang, Zhenlei and Yuan, Jin and Pan, Zhiqiang and Pei, Cheng and Hong, Jing and Yang, Yanning and Zhang, Mingchang and Ke, Xiao and Wang, Xinguo and Luo, Zhu and Ma, Ke and Deng, Yingping},
  title = {Pharmacokinetics, safety and preliminary efficacy of conbercept eye drops for corneal neovascularization: Results from phase I/IIa studies},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70707}
}
Kostenlos starten →